Skip to main content
main-content

Oncology

ESMO Congress 2019

medwireNews attended ESMO 2019 in Barcelona, Spain.
Watch our expert interviews on the major trials.

Expert interviews from ESMO 2019

02-10-2019 | Gastrointestinal cancer | Video

ESMO 2019: Potential of targeted therapy for cholangiocarcinoma shown in ClarIDHy trial

Ghassan Abou-Alfa takes us through the ClarIDHy results, which suggest that ivosidenib could be an option for IDH1-mutated, advanced cholangiocarcinoma (3:37).

01-10-2019 | Urothelial cancer | Video

ESMO 2019: Atezolizumab shows promise in advanced urothelial cancer

Enrique Grande presents the IMvigor130 trial assessing front-line atezolizumab, either as monotherapy or alongside chemotherapy, in treatment-naïve individuals with locally advanced or metastatic urothelial carcinoma (5:54).

30-09-2019 | Breast cancer | Video

ESMO 2019: KEYNOTE-522 points to pembrolizumab role in triple-negative breast cancer

Peter Schmid discusses data pointing to a role for pembrolizumab in the neoadjuvant and adjuvant treatment of newly diagnosed, early-stage triple-negative breast cancer (3:32).

30-09-2019 | Breast cancer | Video

ESMO 2019: MONALEESA-3 OS results demonstrate ribociclib–fulvestrant benefit

Dennis Slamon outlines the MONALEESA-3 findings showing that postmenopausal women with HR-positive, HER2-negative advanced breast cancer derive a survival advantage from combining the CDK4/6 inhibitor ribociclib with fulvestrant (1:47).

29-09-2019 | Breast cancer | Video

ESMO 2019: MONARCH 2 update – OS gain with abemaciclib plus fulvestrant

George Sledge Jr reports overall survival data for the MONARCH 2 trial investigating the addition of the CDK4/6 inhibitor abemaciclib to fulvestrant in women with HR-positive, HER2-negative metastatic breast cancer (2:49).

29-09-2019 | Gynaecological cancer | Video

ESMO 2019: PAOLA-1 supports maintenance olaparib plus bevacizumab for newly diagnosed advanced ovarian cancer

Adding a PARP inhibitor to maintenance bevacizumab therapy improves progression-free survival for advanced ovarian cancer regardless of BRCA mutation status (1:41).

Detection bias may contribute to reduced prostate cancer risk in diabetes

PSA test

The reduced prostate cancer risk seen in men with diabetes may be partly explained by detection bias due to a lower biopsy rate following an elevated prostate-specific antigen test result, population-based study data show.

Different ADT combination therapies offer similar prostate cancer survival benefits

Prostate cancer medicines

Adding docetaxel, abiraterone acetate, enzalutamide, or apalutamide to androgen deprivation therapy  significantly improves survival for men with metastatic hormone-sensitive prostate cancer, with little difference between each drug, a network meta-analysis shows.

Network meta-analysis identifies best clinical choices for EGFR-mutated NSCLC

Pills_syringe

Osimertinib and gefitinib plus pemetrexed-based chemotherapy offer the best survival outcomes for patients with advanced EGFR-mutated non-small-cell lung cancer compared with other first-line treatments, shows a network meta-analysis of randomized trials.

Latest news

14-11-2019 | Oncology | News | Article

No delay in progressive CSPC metastasis with PAP-targeted vaccine

Phase II study data suggest that the prostatic acid phosphatase-encoding pTVG-HP vaccine does not improve metastasis-free survival in men with progressive, nonmetastatic, castration-sensitive prostate cancer.

13-11-2019 | Oncology | News | Article

HLA-I evolutionary divergence linked to ICI response in cancer

HLA class I evolutionary divergence is associated with response to immune checkpoint inhibitor treatment in people with cancer, show data published in Nature Medicine.

12-11-2019 | Oncology | News | Article

Lung cancer undertreatment common in USA, regardless of clinical subtype

Between 2010 and 2014, more than a third of lung cancer patients in the USA received less intensive treatment than recommended, or indeed no treatment at all, shows an analysis of data from the US National Cancer Database.

11-11-2019 | Oncology | News | Article

‘No justification’ for HIV exclusion from ICI trials

Researchers highlight the “almost universal exclusion” of people living with HIV from clinical trials of immune checkpoint inhibitor therapies despite malignancy being the leading cause of morbidity and mortality in this population.

ESMO 2019: Targeted Agent May Improve Survival For IDH1-Mutated Advanced Cholangiocarcinoma

Advanced cholangiocarcinoma patients with an IDH1 mutation may benefit from a targeted therapy

Read the full story on ESMO's oncologyPRO educational website (for registered ESMO members).





Twitter Icon Follow medwireNews

Click here
Image Credits